Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Dec 01, 2008 (Vol. 28, No. 21)

BioRating.com—Your Bio Research Experience

URL:www.biorating.com
  • Clever idea
  • Usefulness unclear
’Tis the season for college football, a sport where virtually everything is determined by the ratings. It seems only fair, therefore, that biotechnology should also reap the benefits of a ratings scheme. The system in question here is aimed at helping users to find the best antibodies for their antigens. Ratings include the Top 10 Best Rated Antibodies and the Top 10 Most Reviewed Manufacturers. Visitors can search for antibodies by name or click on an alphabetical listing of them. The site claims ratings are provided by users though it is not completely clear how (or if) companies are excluded from rating their own products. Antibodies are listed by name and when one clicks on a number in the column called View Antibodies, a listing of all the providers of that antibody is given. A great idea in theory, I’ll be curious to hear from readers how well it works in practice.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good


*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »